Giles FJ, Miller CB, Hurd DD, Wingard JR, Fleming TR, Sonis ST, Bradford WZ, Pulliam JG, Anaissie EJ, Beveridge RA, Brunvand MM, Martin PJ, PROMPT-CT Trial Investigators: A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial)
CS and SS collected clinical data
These observations support the concept that nutritional antioxidant status can buffer ferroptotic stress in the gut (150)
Theoretical Tumor Growth Risk: BPC-157's angiogenic activity raises a theoretical concern that new blood vessel formation at tumor sites from existing or undetected malignancies accelerates tumor growth
The dual action ensures comprehensive metabolic regulation, contributing to significant weight loss and improved metabolic health
This patient is 60 and her skin has never looked better